Results from a case series of patients with hidradenitis suppurativa using adalimumab during the COVID-19 pandemic in Salvador, Bahia, Brazil
DOI:
https://doi.org/10.18226/25253824.v6.n11.06Keywords:
Hidradenitis suppurativa, Adalimumab, Covid-19Abstract
Introduction: Hidradenitis suppurativa (HS) is a skin inflammatory disease of great impact on patients’ life quality, with Adalimumab being one of the main treatments available. However, little is known about the safety of its use during the COVID-19 pandemic. Objectives: To describe the frequency of symptoms related to COVID-19 in patients treated for HS with Adalimumab, adherence to prevention and hygiene measures, and the impact of HS on quality of life through the Dermatology Life Quality Index (DLQI). Methods: This paper is a prospective case series with six patients treated at HUPES-UFBA with Adalimumab. Biweekly telephone interviews were carried out to obtain demographic data and the occurrence of symptoms related to COVID-19, during the use of Adalimumab, adherence to preventive measures against the coronavirus and the DLQI score in the first and last interview, being a DLQI score bigger than 10 considered as disease’s great life impact. Results: Six patients agreed in participate. The main complaints possibly linked to COVID-19 were respiratory (24.6 %) and musculoskeletal (23.3 %); tachycardia (28.0 %) was the main symptom related to Adalimumab use. DLQI initial median was 16 (3-28), and its decrease varied among participants (5.6 % - 100.0 %). It was also seen a good adhesion to preventive measures against COVID-19, but one death COVID-related e 1 loss of follow-up happened. Conclusions: The Adalimumab is an anti-TNF immunobiological, and is associated with greater risk of infections on general population. The dosage used on HS treatment is greater than in other diseases like psoriasis and rheumatoid arthritis. On this study, besides the adhesion to preventive measures and DLQI increase, the COVID-related death and loss of follow-up represents a warning about the drug security, especially in non-vaccinated patients. Bigger studies are needed to affirm causality relation.
References
Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, et al. Consensus on the treatment of hidradenitis suppurativa – Brazilian society of dermatology. Anais Brasileiros de Dermatologia. 2019;94(2):7–19.
Scuderi N, Monfrecola A, Dessy LA, Fabbrocini G, Megna M, Monfrecola G. Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review. Skin Appendage Disorders. 2017;3(2):95–110.
Ianhez M, Schmittt J, Miot HA. Prevalence of hidradenitis suppurativa in Brazil - a population survey. 2018. p. 618–9.
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. British Journal of Dermatology. 2019;180(5):1009–17.
Nesbitt E, Clements S, Driscoll M. A concise clinician’s guide to therapy for hidradenitis suppurativa. International Journal of Women’s Dermatology [Internet]. 2020;6(2):80–4. Available from: https://doi.org/10.1016/j.ijwd.2019.11.004
Chernyshov P v., Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: An update. Vol. 18, International Journal of Environmental Research and Public Health. MDPI AG; 2021.
Mouffak S, Shubbar Q, Saleh E, El-Awady R. Recent advances in management of COVID-19: A review. Vol. 143, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2021.
Li Y, Qi L, Bai H, Sun C, Xu S, Wang Y, et al. Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study. Antimicrobial Agents and Chemotherapy. 2021 Sep 7;
Chilimuri S, Mantri N, Gurjar H, Youthjug KA, Sun H, Gongati S, et al. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience. Journal of the National Medical Association. 2021;
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021 Sep 2;2021(9).
BRASIL M da S. PROTOCOLO DE MANEJO CLÍNICO DO CORONAVÍRUS ( COVID-19 ) NA ATENÇÃO PRIMÁRIA À SAÚDE. 2020;1–38.
BRASIL M da S. DIRETRIZES PARA DIAGNÓSTICO E TRATAMENTO DA COVID-19. 2020.
Reumatologia SB de, Brasil G de E da DII do, Infectologia SB de, Dermatologia SB de. ATUALIZAÇÃO DAS RECOMENDAÇÕES PARA OS PROFISSIONAIS DE SAÚDE E PACIENTES COM DOENÇAS INFLAMATÓRIAS IMUNOMEDIADAS: REUMATOLÓGICAS, DERMATOLÓGICAS E GASTROINTESTINAIS, FRENTE À INFECÇÃO PELO 2019-nCoV (17/03/2020). 2020;(March 2020).
abbvie Pharma. Bula adamimumabe. 2019;1–9.
BRASIL M da S, CONITEC CN de I de T no S. Protocolo Clínico e Diretrizes Terapêuticas Hidradenite Supurativa [Internet]. Available from: http://conitec.gov.br/
Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, del Marmol V, Marzano A v., Prens EP, et al. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Experimental Dermatology. 2021 Jun 1;30(S1):18–22.
Molinelli E, Diotallevi F, Simonetti O, Brisigotti V, Sapigni C, Radi G, et al. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. Dermatologic Therapy. 2020 Nov 1;33(6).
Quaglino P, Fava P, Cariti C, Ortoncelli M, Aimetti M, Milan A, et al. Hidradenitis suppurativa and adalimumab in the COVID-19 era. Vol. 30, European Journal of Dermatology. John Libbey; 2020. p. 747–8.
Blaszczak A, Trinidad JCL, Cartron AM. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. Vol. 83, Journal of the American Academy of Dermatology. Mosby Inc.; 2020. p. e31.
Kearns DG, Chat VS, Uppal S, Wu JJ. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. Vol. 83, Journal of the American Academy of Dermatology. Mosby Inc.; 2020. p. e433–4.
Vardoulakis S, Espinoza Oyarce DA, Donner E. Transmission of COVID-19 and other infectious diseases in public washrooms: A systematic review. Science of The Total Environment [Internet]. 2022 Jan;803:149932. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0048969721050075
Chaabna K, Doraiswamy S, Mamtani R, Cheema S. Facemask use in community settings to prevent respiratory infection transmission: A rapid review and meta-analysis. Vol. 104, International Journal of Infectious Diseases. Elsevier B.V.; 2021. p. 198–206.
Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: Systematic review and meta-analysis. International Journal of Environmental Research and Public Health. 2021 Jul 1;18(13).
Thomsen SF. A note on improvement in dermatology life quality index (DLQI) among patients with hidradenitis suppurativa treated with adalimumab. Vol. 29, Journal of Dermatological Treatment. Taylor and Francis Ltd; 2018. p. 823–4.
Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, et al. Interventions for hidradenitis suppurativa: A Cochrane systematic review incorporating GRADE assessment of evidence quality. Vol. 174, British Journal of Dermatology. Blackwell Publishing Ltd; 2016. p. 970–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Cassio Augusto Estrela Morbeck, Luíse Ribeiro Daltro, Vitória Regina Pedreira de Almeida Rêgo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors keep the copyright and cede to the journal the right of publishing first. Published works are licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, allowing the sharing of the work with recognition of the authorship and initial publication in this journal.
